Brokerages Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Target Price at $73.00

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) have received an average rating of “Moderate Buy” from the eleven ratings firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $81.6667.

A number of brokerages have issued reports on ARWR. HC Wainwright raised their target price on Arrowhead Pharmaceuticals from $85.00 to $100.00 and gave the stock a “buy” rating in a research note on Wednesday. Piper Sandler restated an “overweight” rating and set a $110.00 price objective (up from $100.00) on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, January 13th. Chardan Capital boosted their target price on shares of Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a research note on Wednesday. Finally, Bank of America raised their price target on shares of Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th.

Insider Activity at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 13,187 shares of Arrowhead Pharmaceuticals stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $66.10, for a total value of $871,660.70. Following the sale, the chief executive officer owned 3,792,739 shares in the company, valued at $250,700,047.90. The trade was a 0.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider James C. Hamilton sold 40,164 shares of the company’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $63.11, for a total value of $2,534,750.04. Following the completion of the transaction, the insider directly owned 171,958 shares in the company, valued at approximately $10,852,269.38. This trade represents a 18.93% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 510,836 shares of company stock valued at $33,603,060 over the last 90 days. Corporate insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. PNC Financial Services Group Inc. raised its stake in shares of Arrowhead Pharmaceuticals by 3.1% in the 3rd quarter. PNC Financial Services Group Inc. now owns 10,924 shares of the biotechnology company’s stock valued at $377,000 after acquiring an additional 326 shares during the period. State of Wyoming increased its holdings in Arrowhead Pharmaceuticals by 5.6% in the 3rd quarter. State of Wyoming now owns 9,519 shares of the biotechnology company’s stock valued at $328,000 after purchasing an additional 504 shares during the last quarter. Arizona State Retirement System raised its position in Arrowhead Pharmaceuticals by 1.9% in the third quarter. Arizona State Retirement System now owns 32,661 shares of the biotechnology company’s stock valued at $1,126,000 after purchasing an additional 620 shares during the period. CWM LLC lifted its stake in Arrowhead Pharmaceuticals by 6.7% during the third quarter. CWM LLC now owns 12,179 shares of the biotechnology company’s stock worth $420,000 after purchasing an additional 764 shares in the last quarter. Finally, State of Alaska Department of Revenue boosted its position in shares of Arrowhead Pharmaceuticals by 1.2% during the fourth quarter. State of Alaska Department of Revenue now owns 70,399 shares of the biotechnology company’s stock worth $4,673,000 after buying an additional 831 shares during the period. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Arrowhead Pharmaceuticals

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised several near?term and FY2026/FY2027 EPS estimates, reiterated a “Buy” rating and a $100 price target — the firm says improving forecasts and program progress support upside. HC Wainwright Forecasts Strong Price Appreciation for Arrowhead Pharmaceuticals
• Positive Sentiment: B. Riley bumped its price target to $101 (from $61) and kept a “Buy” stance, implying significant upside from recent levels and signaling continued analyst conviction after Arrowhead’s program updates. B. Riley Raises ARWR Price Target to $101
• Positive Sentiment: Piper Sandler highlighted Arrowhead’s pipeline ahead of Phase III hypertriglyceridemia data and has increased its target (reported lift to $110), underscoring the potential for a clinical readout to re?rate the stock if data are positive. Piper Sandler Highlights Arrowhead Pipeline
• Neutral Sentiment: Broader coverage pieces (InsiderMonkey/TheFly) recap the analyst upgrades and pipeline milestones — useful for context but largely reiterative of the broker notes above. InsiderMonkey: Piper Sandler Highlights Arrowhead
• Negative Sentiment: Despite the upgrades, shares are down today amid lower?than?average volume — likely profit?taking following the recent run and continued investor caution given persistent GAAP losses and upcoming binary clinical readouts (which carry upside but also clinical risk).

Arrowhead Pharmaceuticals Stock Performance

Shares of Arrowhead Pharmaceuticals stock opened at $67.05 on Wednesday. The business’s 50 day moving average price is $62.41 and its 200 day moving average price is $39.95. The company has a market cap of $9.11 billion, a price-to-earnings ratio of -838.02 and a beta of 1.21. The company has a debt-to-equity ratio of 0.43, a quick ratio of 4.86 and a current ratio of 4.86. Arrowhead Pharmaceuticals has a one year low of $9.57 and a one year high of $76.76.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.